Blood pressure will be measured using a validated oscillometric technique, in the sitting position, after 5 to 10 minutes rest and using the same arm throughout the study. Three readings at 1-2 minute intervals will be taken and the mean of the last 2 readings will be used for analysis. Twenty-four hour ambulatory BP monitoring will be performed using a validated oscillometric system. Two 24-hour urine collections for the measurement of sodium, potassium, urea, and creatinine, will be performed at baseline and at the end of the 8-week study period. Blood and urine samples will be taken after an overnight fast (8 - 14 hr) at baseline and then end of the study for measurement of routine biochemistry, plasma renin activity, aldosterone, urinary protein creatinine ratio and urinary albumin creatinine ratio. Blood and urine samples will be taken at baseline and the end of study assessment to look at markers of endothelial function and novel markers of renal dysfunction and fibrosis. These will include EDA+Fibronectin, transforming growth factor-β (TGF-β) and connective tissue growth factor (CTGF).